Abstract: The present invention relates to the field of adjuvant and vaccination. In the present study, the inventors investigate whether P1, in addition to being an antigen, could act as an adjuvant by first exploring its capacity to stimulate epithelial TSLP production. They evaluated additional immunomodulatory effects of P1 on human nasal mucosal models, including cytokines and chemokines production, intracellular signaling pathways, mucosal DC activation, T cell proliferation, and antigen-specific B cell responses against a model antigen in vitro. Altogether, they reported the immunological mechanism underlying P1-vaccine and the interest of P1 as a nasal mucosal adjuvant. Thus, the present invention relates to an immunoadjuvant composition comprising the P1 peptide of the HIV-1 envelope subunit gp41.

Abstract: Novel antibodies and peptides relating to HIV are disclosed, as are vaccine compositions containing such antibodies and peptides. The compounds and compositions of the invention are of use in prevention and treatment of HIV, and in particular for inducing mucosal immunity to HIV.

Abstract: The invention relates to a monoclonal antibody or a fragment thereof comprising in the H chain variable region at least one complementarity determining region (CDR) selected among CDR1, CDR2 and CDR3 having, respectively, an amino acids sequence set forth as SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 or functional analogues thereof.

Abstract: The invention relates to a monoclonal antibody or a fragment thereof, recognizing a peptide of sequence set forth as SEQ ID NO 7 or an analogue thereof, wherein the complementarity determining region 3 (CDR3) of its H chain variable region comprises the peptide sequence set forth as SEQ ID NO 1 or a functional analogue thereof.